CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
PR Newswire
November 21, 2021 β 17:09 CST
UNLOCK DATA Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech